The Company respectfully advises the Staff that it has revised the table on pages 2 and 102 of the S-1 Registration Statement in response to the Staff’s comment to clarify the stages of development of its programs with additional specificity and to more accurately depict the Company’s development pipeline, which includes certain programs partnered with Sanofi and Vertex.
In addition, the Company respectfully advises the staff that the Company considers each of the programs depicted in the pipeline graphic to be material to the Company and its investors for the following reasons:
Rest of the answer
IRAKIMiD, and STAT3 program depicted in the pipeline graphic, beyond our KT-474 program, reflects a high-priority area of focus of the Company’s most advanced discovery efforts. These programs are all in preclinical development with likely clinical entry in 2021. Though development candidates have not yet been identified for all of these programs, the Company believes this disclosure is important to investors in light of its efforts to drive its IRAK4, IRAKIMiD, and STAT3 programs to deliver transformative therapies to patients, as described in its planned use of proceeds;
With respect to the Company’s IRAK4 and IRAKIMiD programs generally, the significant research and development costs incurred with respect to IRAK4 and IRAKIMiD in fiscal year 2019 and the first half of 2020 as described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations”;
With respect to the Company’s lead development candidate KT-474 under its IRAK4 program, the current expectation that the Company will move forward with Phase 1 and Phase 2 clinical development in HS, AD and RA, as described on page 120 of the S-1 Registration Statement;
With respect to the Company’s IRAK4 programs beyond its lead development candidate KT-474, the potential milestone payments attributable to the Company’s IRAK4 program under its collaboration with Sanofi described elsewhere in the S-1 Registration
Statement;
With respect to the Company’s STAT3 programs generally, the significant research and development costs incurred with respect to STAT3 in fiscal year 2019 and the first half of 2020 as described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” including an increase of more than four times the amount of such expense incurred over the same periods in fiscal year 2018 and the first half of 2019;
With respect to the Company’s STAT3 program in autoimmune & fibrotic diseases, the strategic importance of its efforts in these disease areas given their prevalence in the population, the frequency in these disease areas of biological pathways that include previously undrugged or inadequately drugged targets, and the potential synergies with the Company’s lead development efforts in IRAK4;
With respect to the Company’s discovery pipeline partnered with Vertex, the potential milestone payments attributable to those programs under its collaboration with Vertex described elsewhere in the S-1 Registration Statement;
With respect to the Company’s discovery pipeline partnered with Sanofi, the potential milestone payments attributable to those programs under its collaboration with Sanofi described elsewhere in the S-1 Registration Statement; and
With respect to the Company’s internal discovery pipeline, the significant development efforts and expenses undertaken in connection with building out its Pegasus Platform and potential validating of our technology beyond our lead programs while leveraging the Company’s capabilities in E3 ligase biology and chemistry that it expects will result in differentiated and transformative therapies.